These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1192 related articles for article (PubMed ID: 30837838)

  • 1. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.
    Prasad A; Bharathi V; Sivalingam V; Girdhar A; Patel BK
    Front Mol Neurosci; 2019; 12():25. PubMed ID: 30837838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.
    Tamaki Y; Urushitani M
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations.
    Maekawa S; Leigh PN; King A; Jones E; Steele JC; Bodi I; Shaw CE; Hortobagyi T; Al-Sarraj S
    Neuropathology; 2009 Dec; 29(6):672-83. PubMed ID: 19496940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
    Prudlo J
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational insights into mechanism of AIM4-mediated inhibition of aggregation of TDP-43 protein implicated in ALS and evidence for in vitro inhibition of liquid-liquid phase separation (LLPS) of TDP-43
    Girdhar A; Bharathi V; Tiwari VR; Abhishek S; Deeksha W; Mahawar US; Raju G; Singh SK; Prabusankar G; Rajakumara E; Patel BK
    Int J Biol Macromol; 2020 Mar; 147():117-130. PubMed ID: 31917988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization.
    Prasad A; Sivalingam V; Bharathi V; Girdhar A; Patel BK
    Biochimie; 2018 Jul; 150():76-87. PubMed ID: 29751083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.
    Gomez-Deza J; Lee YB; Troakes C; Nolan M; Al-Sarraj S; Gallo JM; Shaw CE
    Acta Neuropathol Commun; 2015 Jun; 3():38. PubMed ID: 26108573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.
    Troakes C; Maekawa S; Wijesekera L; Rogelj B; Siklós L; Bell C; Smith B; Newhouse S; Vance C; Johnson L; Hortobágyi T; Shatunov A; Al-Chalabi A; Leigh N; Shaw CE; King A; Al-Sarraj S
    Neuropathology; 2012 Oct; 32(5):505-14. PubMed ID: 22181065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 cytoplasmic inclusion formation is disrupted in
    Lee SM; Asress S; Hales CM; Gearing M; Vizcarra JC; Fournier CN; Gutman DA; Chin LS; Li L; Glass JD
    Brain Commun; 2019; 1(1):fcz014. PubMed ID: 31633109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43.
    Watanabe S; Inami H; Oiwa K; Murata Y; Sakai S; Komine O; Sobue A; Iguchi Y; Katsuno M; Yamanaka K
    Cell Death Dis; 2020 Oct; 11(10):909. PubMed ID: 33097688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
    Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
    Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTLD/ALS-linked TDP-43 mutations do not alter TDP-43's ability to self-regulate its expression in Drosophila.
    Miguel L; Avequin T; Pons M; Frebourg T; Campion D; Lecourtois M
    Brain Res; 2018 Sep; 1695():1-9. PubMed ID: 29778779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation.
    French RL; Grese ZR; Aligireddy H; Dhavale DD; Reeb AN; Kedia N; Kotzbauer PT; Bieschke J; Ayala YM
    J Biol Chem; 2019 Apr; 294(17):6696-6709. PubMed ID: 30824544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
    Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
    Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
    Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and pathological spectrum of TDP-43 associated ALS].
    Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
    Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zn
    Preethi S; Bharathi V; Patel BK
    Int J Biol Macromol; 2021 Apr; 176():186-200. PubMed ID: 33577819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.